CommercialPrior AuthMedium impact
Policy Criteria Change
Arkansas Blue Cross Blue Shield·AR · Oncology, Hematology, Rheumatology·Medical Policy
Effective date
May 20, 2026
We identified it
Jun 19, 2026
Summary
Arkansas Blue Cross updated coverage criteria for several specialty oncology drugs, adding continuation therapy requirements and expanding off-label coverage for various cancer treatments. The changes primarily affect oncology billing with new prior authorization criteria for drug continuation.
Action Required
By May 20, 2026: Oncology practices must update prior authorization processes to include new continuation criteria for Loncastuximab, Cabazitaxel, Talquetamab, Siltuximab, Polatuzumab, Margetuximab, and Obinutuzumab. Documentation must now include objective benefit measures, disease stabilization evidence, and ECOG performance status for specific drugs. Update prior auth templates to reflect expanded off-label indications for multiple myeloma, B-cell lymphomas, and lupus nephritis.